Carisma Therapeutics Inc. has been granted an extension by a Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market. This decision follows a plan presented by the company to comply with Nasdaq's listing criteria. The company's listing is set to be transferred to the Nasdaq Capital Market on June 12, 2025. Carisma must demonstrate a closing bid price of $1.00 or more per share for at least ten consecutive trading sessions, complete a strategic transaction, and meet all initial listing requirements by October 7, 2025. The Panel has emphasized that it cannot extend the listing beyond this date for noncompliance. Carisma is also required to meet an interim milestone related to its strategic process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.